Introduction
Monoclonal
antibodies (mAbs) have emerged as a game-changing class of therapeutic agents,
changing the face of modern medicine. These modified antibodies are intended to
target specific molecules in the body, and their creation has become an
essential component of biopharmaceutical research and development.
Monoclonal Antibodies
Monoclonal
antibodies are antibodies that have been engineered to replicate the body's
natural immunological response. Unlike polyclonal antibodies, which are
generated by a broad population of immune cells, monoclonal antibodies (mAbs)
are produced by a single kind of immune cell, usually a B cell clone. They get
their name from their monoclonal nature. mAbs are proteins or cells that are
intended to recognise and bind to particular antigens linked with illnesses
such as cancer, autoimmune disorders, and infectious diseases.
The significance of Monoclonal
Antibodies
1) Precision medicine
one of the
most significant advantages of monoclonal antibodies. They may be customised to
target a specific chemical or cell type while causing little collateral harm to
healthy cells and tissues. This accuracy is especially useful in cancer
therapy, as mAbs may attack cancer cells specifically.
2) Chronic Disease Treatment
mAbs have
transformed the treatment of a variety of chronic disorders, including rheumatoid
arthritis, multiple sclerosis, and inflammatory bowel disease. They help
control symptoms and enhance patients' quality of life by modifying the immune
system's reaction.
3) Infectious disease
Monoclonal
antibodies have been at the vanguard of the fight against infectious illnesses.
During the COVID-19 pandemic, for example, numerous mAbs were created to
neutralise the SARS-CoV-2 virus, providing an extra weapon to battle the
pathogen.
Production
of Monoclonal Antibody
From
identifying the suitable antigen target to large-scale manufacturing, the
synthesis of monoclonal antibodies requires multiple difficult procedures.
Here's a rundown of the procedure:
1) Antigen Identification
The first
stage is to determine which antigen or target the mAb will recognise. This
antigen is frequently a disease-associated protein, such as a cancer cell
marker or a viral protein.
2) Immunisation
An animal,
generally a mouse, is immunised with the antigen of choice in order to elicit
an immunological response. The immune system of the mouse generates a wide
collection of antibodies, including those that bind to the antigen of interest.
3) B Cell Isolation
B cells,
which are responsible for antibody synthesis, are isolated from the spleen of a
mouse. These B cells contain a variety of antibodies, including those that
specifically target the targeted antigen.
4) Fusion
Hybridomas
are formed when B cells combine with myeloma cells (cancerous plasma cells).
These hybridomas can manufacture antibodies forever while retaining the
original B cell's specificity.
5) Screening
The
hybridomas are examined to see which ones generate the appropriate monoclonal
antibody. Several tests are used in this procedure to confirm specificity and
potency.
6) Purification
To eliminate
any impurities, the monoclonal antibodies are purified from the culture medium.
This phase guarantees that the finished product is both safe and effective for
medicinal purposes.
7) Formulation and packaging
Purified
antibodies are made into a suitable pharmaceutical product before being
packaged for distribution and usage.
